{"id":"NCT00374907","sponsor":"AstraZeneca","briefTitle":"A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","officialTitle":"Mechanism of Action and Efficacy of Saxagliptin (BMS-477118) in the Treatment of Type 2 Diabetic Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2008-01","completion":"2009-12","firstPosted":"2006-09-12","resultsPosted":"2011-01-21","lastUpdate":"2015-05-07"},"enrollment":156,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Saxagliptin","otherNames":["BMS-477118"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Metformin (blinded)","otherNames":[]},{"type":"DRUG","name":"Metformin (open-label)","otherNames":[]}],"arms":[{"label":"Saxagliptin (A)","type":"EXPERIMENTAL"},{"label":"Placebo (ST) / Metformin (LT) (B)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes","primaryOutcome":{"measure":"Insulin Secretion Rate Area Under the Curve (AUC) During Intravenous (IV)-Oral Hyperglycemic Clamp - Percent Change From Baseline at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Short Term Period: Saxagliptin 5 mg","deltaMin":15.9,"sd":null},{"arm":"Short Term Period: Placebo","deltaMin":-2.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0350"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":2},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":16},"commonTop":["HEADACHE","NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","INFUSION SITE PAIN","NAUSEA"]}}